Solid Biosciences Inc. Common Stock (SLDB) Stock
NASDAQ · SLDB
Key stats
- Market cap
- $848.24M
- Price / Earnings ratio
- -3.7x
- EPS (TTM)
- -$1.79
- Volume
- Loading
- 52-week high
- $11.45
- 52-week low
- $4.05
Source: third-party data provider, as of November 13, 2026
Compare with SLDB
Recent news

Stocktwits
Capricor Says FDA Used 'Obsolete' Analysis In Deramiocel Review – CAPR Stock Plummets After Agency Released Briefing Document
SLDBJuly 27, 2026
Stocktwits
Capricor Says FDA Used 'Obsolete' Analysis In Deramiocel Review – CAPR Stock Plummets After Agency Released Briefing Document
SLDB

New York Post
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
SLDBMarch 31, 2025
New York Post
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
SLDB

24/7 Wall Street
More Big Warren Buffett Purchases Highlight Recent Insider Buying
SLDBJanuary 20, 2024
24/7 Wall Street
More Big Warren Buffett Purchases Highlight Recent Insider Buying
SLDB

MarketBeat
Are Gene Therapy Stocks The Market's Next Big Winners?
SLDBSeptember 25, 2023
MarketBeat
Are Gene Therapy Stocks The Market's Next Big Winners?
SLDB
Technical indicators
- RSI 14
- 62.21
- MACD 12/26/9
- -0.01
- EMA 9 of MACD
- -0.23
- MACD histogram
- 0.23
- SMA 50
- $7.33
- Price above SMA 50
- EMA 50
- $7.12
- Price above EMA 50
- SMA 200
- $7.68
- Price below SMA 200
- EMA 200
- $7.21
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Strong Sell0
Sell0
Hold0
Buy6
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
16M11M5M0
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
312M206M103M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-174.3M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Stocktwits
Capricor Says FDA Used 'Obsolete' Analysis In Deramiocel Review – CAPR Stock Plummets After Agency Released Briefing Document
SLDBJuly 27, 2026
Stocktwits
Capricor Says FDA Used 'Obsolete' Analysis In Deramiocel Review – CAPR Stock Plummets After Agency Released Briefing Document
SLDB

New York Post
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
SLDBMarch 31, 2025
New York Post
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
SLDB

24/7 Wall Street
More Big Warren Buffett Purchases Highlight Recent Insider Buying
SLDBJanuary 20, 2024
24/7 Wall Street
More Big Warren Buffett Purchases Highlight Recent Insider Buying
SLDB

MarketBeat
Are Gene Therapy Stocks The Market's Next Big Winners?
SLDBSeptember 25, 2023
MarketBeat
Are Gene Therapy Stocks The Market's Next Big Winners?
SLDB

InvestorPlace
7 Sizzling Stocks That Are Oblivious to the Manic Market
SLDBOctober 20, 2022
InvestorPlace
7 Sizzling Stocks That Are Oblivious to the Manic Market
SLDB
About Solid Biosciences Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees121
CEOMr. Alexander G. Cumbo
IPO DateJan 25, 2018
HeadquartersCharlestown, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Alexander G. Cumbo | President, CEO & Director | 1971 |
| Mr. Ilan Ganot | Co-founder, Strategic Advisor to the CEO & Director | 1974 |
| Mr. Ian F. Smith A.C.A., C.P.A. | Executive Chair | 1966 |
| Mr. David Tyronne Howton Jr., J.D. | COO & Secretary | 1972 |
| Mr. Kevin Tan C.F.A. | CFO & Treasurer | 1978 |
| Dr. Gabriel Brooks M.D. | Chief Medical Officer | 1977 |
| Ms. Annie Ganot | Co-Founder & VP of Patient Advocacy | — |
| Mr. Paul Herzich | Chief Technology Officer | 1978 |
| Ms. Nicole Anderson | Senior Director of Investor Relations & Corporate Communications | — |
| Dr. Jessie Hanrahan Ph.D. | Chief Regulatory & Preclinical Operations Officer | 1976 |
Fundamentals
Valuation
Price-to-book value2.34
Profitability
Return on Equity-68.00%
Return on Assets-59.00%
EBITDA$-211.50M
Trading
Average volume1,437,250
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 62.21
- MACD 12/26/9
- -0.01
- EMA 9 of MACD
- -0.23
- MACD histogram
- 0.23
- SMA 50
- $7.33
- Price above SMA 50
- EMA 50
- $7.12
- Price above EMA 50
- SMA 200
- $7.68
- Price below SMA 200
- EMA 200
- $7.21
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Buy
100% Buy
0% Hold
0% Sell
Analyst price target
- Low
- $18.00
- Average
- $21.80
- High
- $26.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -19.4 | +2.9 | ||||||||||
| 2022 | -31.5 | -36.8 | +49.4 | -54.5 | +3.6 | +8.0 | +17.2 | -6.4 | -29.3 | -13.7 | +6.3 | -19.1 |
| 2023 | +34.9 | -25.5 | -13.8 | +2.3 | +16.8 | -16.8 | -17.4 | -12.6 | -30.4 | -9.0 | +20.0 | +104.0 |
| 2024 | +10.2 | +32.4 | +36.3 | -28.7 | -13.4 | -31.3 | +42.3 | +3.4 | -17.7 | -18.6 | -0.9 | -30.9 |
| 2025 | -18.5 | +77.5 | -27.7 | -4.1 | -12.1 | +37.6 | +48.7 | -19.8 | +13.6 | -8.2 | +4.4 | +8.3 |
| 2026 | +18.5 | -3.4 | +16.1 | -1.6 | +2.9 | +38.9 | -21.0 | +19.5 | -26.8 | -11.2 | +26.7 |
Compare stocks
Market cap
$848.24M
-
-
-
Price / Earnings ratio
-3.70
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
1,437,250
-
-
-
Earnings per share
$-1.79
-
-
-



